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The development of new therapeutic agents for the mitigation of pediatric disorders is
largely hindered by the inability for investigators to assess pediatric pharmacokinetics (PK) in
healthy patients due to substantial safety concerns. Pediatric patients are a clinical moving
target for drug delivery due to changes in absorption, distribution, metabolism and excretion
(ADME) and the potential for PK related toxicological (T) events to occur throughout
development. These changes in ADMET can have profound effects on drug delivery,
and may lead to toxic or sub-therapeutic outcomes. Ethical, economical, logistical, and
technical barriers have resulted in insufﬁcient investigation of these changes by industrial,
regulatory, and academic bodies, leading to the classiﬁcation of pediatric patients as
therapeutic orphans. In response to these concerns, regulatory agencies have incentivized
investigation into these ontogenic changes and their effects on drug delivery in pediatric
populations. The intent of this review is to brieﬂy present a synopsis of the development
changes that occur in pediatric patients, discuss the effects of these changes on ADME
and drug delivery strategies, highlight the hurdles that are still being faced, and present
some opportunities to overcome these challenges.
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INTRODUCTION
Dr. Harry Shirkey of the Children’s Hospital in Alabama orig-
inally described pediatric populations as “therapeutic orphans”
in a 1962 manuscript because of children’s neglected status dur-
ing drug development (Shirkey, 1968). Approximately 50 years
later, the aversion to developing new therapeutic agents for chil-
dren still stands. This aversion is attributable to a variety of
factors, including ethical concerns associated with testing drugs
in children, the lack of ﬁnancial return on investment due
to smaller patient populations, biological challenges resultant
of physiological maturation/development, lack of centers with
trained clinicians to conduct pediatric clinical trials, and formula-
tion challenges to improve patient compliance (Milne and Bruss,
2008). In response to these challenges, the United States FDA
has issued legislation such as the Best Pharmaceuticals for Chil-
dren Act (BPCA) and the Pediatric Research Equity Act (PREA)
to provide incentives for testing and developing drugs for chil-
dren. Similar incentives and initiatives have been advanced by
regulatory agencies throughout the world. While these incen-
tives have signiﬁcantly improved pediatric drug labeling and
increased the number of clinical trials being performed in chil-
dren, a large unmet need still exists for the development of
child-friendly dosage forms (Hoppu et al., 2012). Toward this
point, the World Health Organization estimated that more than
7.6 million deaths in children under the age of 5 occurred world-
wide in 2010, with greater than 99% of these deaths occurring
in low to middle income countries. While some of these deaths
are the result of prenatal complications, the yearly number of
preventable childhood deaths, e.g., symptoms of communicable
diseases, still lies in the millions. Clearly, the therapeutic interven-
tion of pediatric disorders remains a critical area for continued
research.
The pediatric population, especially in the neonatal to infant
stages of development, represent a dynamic group in respect to
physiology. Through the recognition brought on by the legisla-
tion described above there has been an increase in activity to seek
answers to the challenges faced in determining how to safely and
effectively deliver medicines to children (Gazarian, 2009). From
this activity, many questions have begun to be answered, but many
still have yet to be addressed. Throughout this review, we will
present challenges associated with and opportunites to develop
age appropriate peroral drug dosage forms for children, particu-
larly in the neonatal, infant, and toddler stages of development.
Hence, we will dissect and highlight some of the signiﬁcant chal-
lenges that must be overcome in order for investigators to make
signiﬁcant inroads in the ﬁeld.
Traditionally, pediatric doses are developed through allometric
scaling of adult doses using metrics such as ratios of body surface
area or body weight (Bartelink et al., 2006; Gazarian, 2009; Tucker,
2009; Ansel, 2010; De Cock et al., 2011). For example, initial doses
are often calculated from adult clearance values, which factors
in endogenous increases in liver volume by taking body weight
to the 3/4 power (Bartelink et al., 2006; Gazarian, 2009; Tucker,
2009; Ansel, 2010). The principal limitation to this approach
is that this method is only useful in later stages of child devel-
opment, since it only accounts for changes in organ size and
assumes that the pharmacokinetic and pharmacodynamic prop-
erties are the same (Ansel, 2010). This is an invalid assumption in
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earlier developmental stages since the morphology and ontogeny
of critical drug metabolizing and transporting isoforms and their
regulatory systems change in organs from the neonatal to infant
stage of childhood (De Wildt et al., 1999; Johnson, 2003; Kearns
et al., 2003; Björkman, 2005; Bartelink et al., 2006; Gazarian, 2009;
Kramer, 2009; Tucker, 2009; De Cock et al., 2011). Therefore,
developmental changes are a considerable concern and may have
signiﬁcant effects that render ratio calculations useless for younger
children, leading to the phrase that children are not little adults
(De Wildt et al., 1999; Milne and Bruss, 2008).
It is currently recognized that the research into the design of
pediatric doses must be predicated on the acquisition of data using
a combination of bottom up and top down methods (De Wildt
et al., 1999; Kearns et al., 2003; Björkman, 2005; De Cock et al.,
2011). Bottom up methods use diverse and discrete pieces of prior
physiological and genetic information together with in vitro data
to rationally try and anticipate in vivo changes in pediatric dose
safety and efﬁcacy. The use of physiological based pharmacoki-
netic (PBPK) modeling approaches can aid in the extrapolation
of pediatric doses made in the bottom up stages (De Wildt et al.,
1999; Kearns et al., 2003; Björkman, 2005; Ansel, 2010; De Cock
et al., 2011). The bottom up approach can be used to select a
dose or a range of doses, which are then conﬁrmed to be safe
and efﬁcacious by top down methods. Top down methods rely
on the administration of doses and use of the plasma concentra-
tion versus time data from the population of interest to assess if
co-variates such as age result in predictable changes. It is impor-
tant to note that many of the clinical studies are ﬁrst conducted
in adults. Furthermore, this approach is utilized when either
a signiﬁcant history of adult use of the medication is present
or when there is a signiﬁcant risk from the disease that out-
weighs the concerns arising for potential drug-related adverse
effects.
PHYSIOLOGICAL CONSIDERATIONS REGARDING PEDIATRIC
PHARMACOKINETICS
The PK of a drug is predicated on the absorption, distribution,
metabolism, and excretion (ADME) of an individual drug upon
administration. The goal of any dosing regimen is to provide
consistent and predictable systemic drug exposure drug in the
patient resulting in a safe and efﬁcacious response. Ontogenic
morphological and drug metabolizing and transporter expres-
sion changes have a profound effect on ADME, particularly in
the ﬁrst 18 months of life (Kramer, 2009). In fact, these changes
inﬂuence all parts of ADME. For instance, absorption through
the GI tract may be affected by changes in morphology of the
GI epithelium, increased body fat percent in pediatric patients
may inﬂuence distribution of lipophilic drugs, changes in CYP450
expression can alter drug metabolism rates, and development
of kidney function in pediatric patients can impact excretion
in the urine. Because of these rapid changes in growth and
development, it is extremely difﬁcult to give general dosing
requirements particularly for prenatal, infant, and toddler pop-
ulations (De Wildt et al., 1999; Johnson, 2003; Kearns et al., 2003;
Björkman, 2005; Bartelink et al., 2006; Kearns, 2009; Kramer,
2009; Tucker, 2009; De Cock et al., 2011). We will highlight some
representative examples of physiological changes that inﬂuence
ADME during different stages of development to demonstrate
how these differences impact decisions on the drug dose. It
must be emphasized that these generalizations are based on
assumptions that may not apply to each speciﬁc drug, the spe-
ciﬁc disease state being treated, or other potential factors that
have not yet been fully realized. Speciﬁc dosage regimens from
this model simply act as a guide when no data exist and/or
for doing clinical testing that will be discussed in the next
section.
ABSORPTION
A drug administered extravascularly must overcome a variety
of chemical, physical, mechanical, and biological barriers to be
absorbed. The extent of drug absorption from a dosage form is
referred to as the bioavailability. In general, absorption across the
gastrointestinal (GI) epitheliumoccurs via either a single or a com-
bination of several permeation routes including the paracellular
route (hydrophilic, diffusion between cellular junctions), passive
transcellular (lipophilic, across the lipid bilayers of the apical and
basolateral membranes), by active transporters (inﬂux or efﬂux),
metabolism, and in some cases endocytosis. We will not elaborate
upon these routes for the sake of brevity.
In the neonatal, infant, and toddler age groups, peroral for-
mulations are often solution based such as syrups or suspensions.
Solid dosages are often avoided based on the difﬁculty that these
age groups have in swallowing, yet they may offer a considerable
safety advantage when considering differences in the rates of drug
degradation in solutions vs. solids. The development of sprin-
kles, oral dissolving ﬁlms and oral disintegrating tablets do offer
promise to overcome the stability challenges.
Peroral drug absorption is primarily affected by developmental
changes in the GI tract. Perhaps the most commonly discussed
difference in the neonatal period is the elevation of intragastric
pH, which can affect the ionization, stability and absorption of
different drugs (Kearns et al., 2003; Bartelink et al., 2006; Kramer,
2009). Gastric pH values are in the range of 6–8 at birth, and
drop within hours to 2–3. However, after the ﬁrst 24 h of life,
the gastric pH begins to elevate to more alkaline levels due to
the immature parietal cells which are responsible for secreting
gastric acid (Kearns et al., 2003). Other GI differences that change
withdevelopment include: variable effects on gastric emptying and
intestinal transit time, which are often prolonged through child-
hood due to reduced motility; immature biliary function, leading
to reduced ability to solubilize lipophilic drugs including vitamins;
reduction in intestinal metabolizing enzymes, which may lead to
a higher fraction absorbed for some drugs; reduced splanchnic
blood ﬂow, which could lead to decreased permeation from the
cells of the GI tract to the bloodstream; and a reduction in the
intestinal microﬂora (Johnson, 2003; Kearns et al., 2003; Bartelink
et al., 2006; Kearns, 2009; Kramer, 2009). The expression level of
drug transporters has not been fully explored, but is a topic of
considerable interest in the ﬁeld (Kearns et al., 2003). There are
two generalizations that can be made concerning development
stage dependent changes in transporter expression and function:
(1) diet plays a critical role in controlling the relative transport
activities over time; (2) there is a general decrease in the trans-
porter activity as a function of intestinal surface area due to the
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large increase in surface area that occurs throughout development
(Buddington, 1992).
These physiological changes are representative of a variety of
effects that may alter the oral absorption of a drug from a for-
mulation. Moreover, oral administration of drugs to neonates,
especially in the ﬁrst 2 weeks, is generally changed to account for a
reduced bioavailability unless there is a signiﬁcant ﬁrst-pass effect
or if the drug is acid-labile (Bartelink et al., 2006). It is also well
known that gastric retention and increased GI motility alter the
absorption of enteric coated formulations administered in infants
up to about 3–4 months of age. Finally, rectal administration,
while common for compounded drugs, is cautioned due to high
amplitude pulsatile contractions in the rectum that can increase
the chance of dosage formexpulsion in early stages of development
(Kearns et al., 2003; Bartelink et al., 2006).
DISTRIBUTION
In general, development differences in the rates of maturation of
organs, blood perfusion, percentage of extravascular water, body
fat percentage, differential permeation rates into tissues and dis-
ease states predominantly inﬂuence drug distribution in pediatric
patients. Organ maturation is particularly important in neonates
and infants, as there are continuous changes until the organs begin
to reach maturation. Permeation will vary as barriers to perfusion
across the pediatric endothelium are also continuously changing
until the cells reach a level of stability (Hoppu et al., 2012).
Drug distribution may be affected by changes in body compo-
sition, such as total body water and adipose tissue that may not
necessarily be related to changes in the total body weight. As the
newbornmatures from a neonate, twomajor changes occur in that
the extracellular water decreases and body fat increases (De Wildt
et al., 1999). For example, the extracellular water drops from 40%
of total body weight at birth to about 20% within in 4 months,
thus altering the volume of distribution (VD) in hydrophilic, low
plasma protein binding drugs. Alternatively, the increases in the
percentage of body fat can cause highly lipophilic drugs to have
an increased VD during this time. The levels of these body ﬂuids
continue to ﬂuctuate throughout the ﬁrst 3 years of life, before
they level off (De Wildt et al., 1999).
Plasma protein binding and tissue binding changes also arise
from changes in body composition with growth and develop-
ment that may inﬂuence the VD and clearance (De Wildt et al.,
1999). In general, there is a decrease in protein binding due to
a decreased amount of plasma proteins, like α1-acid glycopro-
tein, and a fetal form of albumin that has a decreased afﬁnity
for weak acids. Beyond that, an increase in circulating biliru-
bin leads to a reduction in binding sites. Depending on the
drug, this can alter the fraction unbound and affect the safety
and efﬁcacy of medicament. For example, in a study to deter-
mine the PK of midazolam, the fraction unbound was higher
in infants at 0.031 compared to adult values of 0.024 (Björk-
man, 2005). Traditionally, we focus on the passive transcellular
(lipophilic) and paracellular (hydrophilic) routes of permeation.
Interestingly, research has indicated a progressive increase in the
ratios of the brain to plasma phenobarbital ratios from 28 to
39 weeks. The authors suggested the results indicate the increase
in brain uptake is potentially due to changes in blood ﬂow
(perfusion) and pore density (paracellular distribution) across
the blood-brain barrier (Painter et al., 1981). There is an excel-
lent database maintained by Workman et al. (2013) that provides
more detailed information regarding developmental changes in
the human brain and potential correlations with other species for
scaling purposes1.
METABOLISM
Amongst the greatest changes that occur and inﬂuence pedi-
atric PK in the early stages of development is their ability to
metabolize drug molecules (De Wildt et al., 1999; Johnson, 2003;
Kearns et al., 2003; Kearns, 2009). Drug metabolism usually occurs
in the liver, but may also occur in the blood, GI wall, kid-
ney, lung, and skin (Kearns, 2009). We will focus on hepatic
metabolism, but it should be noted that there are also signiﬁcant
changes in systemic metabolism that occur during development.
In general, metabolism refers to the biotransformation of drug
entities by enzymes, although transporters are sometimes included
under metabolism. There are several excellent, more compre-
hensive reviews of drug metabolizing enzyme ontogeny in the
literature.
As a brief review, the primary reason for metabolism is to make
lipophilic xenobiotics more polar for excretion from the body as
opposed to accumulation in fatty tissues (Coleman, 2006). Phase
I metabolism generally refers to oxidative enzymes, usually in the
Cytochrome P450 (CYP) family, that lead to oxidative reactions.
However, non-CYP mediated oxidative metabolism, e.g., hydroly-
ses, can also be catalyzed by Phase I enzymes (Coleman, 2006).
Phase II metabolism is generally referred to as metabolism by
addition, where a functional group(s) is often targeted for conju-
gation of hydrophilic molecules. Phase III metabolism is excretion
of the metabolite by efﬂux transporters. Phase I, II, and/or III
metabolism can occur in concert to detoxify cells by removing
lipophilic xenobiotics and dramatically inﬂuence ADME (Cole-
man, 2006). Based on in vitro and in vivo studies, three potential
ontogenic changes in the expression of these enzymes are observed
duringdevelopment: (1) the enzymemight exhibit high expression
during or shortly after birth, followed by a signiﬁcant reduction in
expression levels during the ﬁrst years of life; (2) the enzymemight
have a relatively constant expression levels maintained throughout
gestation with minimal changes occurring postnatally; or (3) the
enzyme may not be expressed, or expressed at low levels, in the
fetus with substantial increases in enzyme level during the ﬁrst
years of life (Kearns, 2009).
The Cytochrome P450 isoforms are the most studied enzymes
in humans, with the CYP1, CYP2, and CYP3 subfamilies com-
monly associated with drug metabolism (De Wildt et al., 1999).
The CYP3A family is the most abundant subfamily and displays
interesting patterns of expression from birth into adulthood. For
example, studies have illustrated that CYP3A4 mRNA, the most
common CYP3A isoform found in adults, is virtually undetectable
in infants (De Wildt et al., 1999). Whereas, the CYP3A7 isoform,
which has relatively low to undetectable levels in adults, consti-
tutes approximately 32% of the total CYP content in the early
human fetal liver (De Wildt et al., 1999; Johnson, 2003; Kearns
1http://www.translatingtime.net/
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et al., 2003; Kearns, 2009). Interestingly, the expression levels of
CYP3A7 quickly decline within the ﬁrst week of life and are
replaced by a gradual increase in the level of CYP3A4 expres-
sion. Subsequently, this may have little effect on hepatic clearance
for many drugs because the actual level of the entire subfam-
ily of CYP3A remains fairly constant throughout this period and
CYP3A4 is 90% homologous to CYP3A7 (De Wildt et al., 1999).
However, further clariﬁcation is needed. Nonetheless, the results
of a study examining the PK of midazolam demonstrated that
the CYP3A4 and 3A7 ontogeny affected clearance (Payne et al.,
1989). In this study, it was determined that CYP3A7 had a dras-
tically reduced afﬁnity for this drug compared to CYP3A4, which
resulted in weight adjusted clearance that followed the ontogenic
expression of CYP3A4. Other CYP enzyme changes that occur
during development include 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and
2E1 (Johnson, 2003; Kearns et al., 2003; Kearns, 2009). Each of
these CYP isoforms have similar expression patterns as observed
with CYP3A4, where they are expressed at low levels at birth and
gradually increase to a steady state within the ﬁrst year of life. A
table of the ontogeny of common Phase I enzymes is shown in
Table 1.
For the phase II enzymes, there is usually a low level of
expression at birth, followed by a gradual increase through-
out infancy. For example, several uridine 5′-diphospho-
glucuronosyltransferase (UGT) isoforms including UGT1A1, 1A4
and 2B7 have very low hepatic expression at birth (Zaya et al.,
Table 1 | Phase I drug metabolizing enzymes
Gene Category Age upon reaching adult expression
CYP1A1 I Birth
CYP1A2 III 1M-1Y
CYP2A III 1M-1Y
CYP2C III Birth
CYP2D6 III Birth
CYP2E1 II –
CYP2J II –
CYP3A4 III Birth
CYP3A5 III Birth
CYP3A7 I 1M-1Y
FMO1 I Birth
ADH1 I 1M-1Y
ADH2 II Prenatal
ADH3 II Prenatal
Ontogenic changes in phase II drug metabolizing enzymes. Categories: I,
higher expression before or just after birth with potential decreasing expres-
sion throughout development to adulthood.; II, Consistent expression throughout
development and potentially throughout adulthood; III, lower expression during
beginning of development with potential increasing throughout development to
adulthood. Ontogenic Appearance/Disappearance: prenatal, ontogenic changes
occur before birth; Birth, ontogenic changes occur at or shortly after birth; 1M-1Y,
ontogenic changes occur between ﬁrst month and year postnatally; –, no change
is seen throughout development. Adapted from reference (Hines and McCarver,
2002)
2006; Miyagi andCollier, 2007,2011; Miyagi et al., 2012). UGT1A6
expression and function at birth is believed to be nearly 50% of
the adult levels and activity (Miyagi et al., 2012). Interestingly,
the expression of UGT1A9 appears to be absent at birth, but the
changes in protein expression seemed to correlate with changes
in the metabolism of 4-methylumbelliferone speciﬁcally inhibited
by niﬂumic acid in children (Miyagi et al., 2012). The correlation
did not hold true for adults, where activities did not correlate with
protein exposure and environmental factors were proposed to be
confounding. Evidence of this can also be observedwithmorphine
through research demonstrating that glucuronidation is detected
in infants as young as 24weeks of age and then quadruples between
27 and 40 weeks, thus requiring a substantial increase in dose to
maintain the same level of effectiveness (Kearns et al., 2003). A
table of the ontogeny of common Phase I enzymes is shown in
Table 2.
Since both phase I and phase II enzymesmay be immature, scal-
ing a dose from adults cannot be done during the ﬁrst 2 months
for drugs that have extensive hepatic metabolism (Bartelink et al.,
2006; Kearns, 2009). Due to the changes in enzymes, if a drug
is metabolized signiﬁcantly, there needs to be individual drug
determinations for how to dose. During the early stages of devel-
opment, the best approach is to start with a low dose and conduct
therapeutic drug monitoring to determine clearance (Bartelink
et al., 2006). From two to 6 months, hepatic metabolism starts to
Table 2 | Phase II drug metabolizing enzymes.
Gene Category Age upon reaching adult expression
GSTA1 II –
GSTA2 II –
GSTM II –
GSTP1 I 1M-1Y
NAT2 II –
UGT1A1 III Birth
UGT1A3 II –
UGT1A6 III Birth
UGTB7 II –
UGTB17 II –
EPHX1 II –
EPHX2 II –
SULT1A1 II –
SULT1A3 II –
SULT2A1 III Prenatal
Ontogenic changes in phase II drug metabolizing enzymes. Categories: I,
higher expression before or just after birth with potential decreasing expres-
sion throughout development to adulthood.; II, Consistent expression throughout
development and potentially throughout adulthood; III, Lower expression during
beginning of development with potential increasing throughout development to
adulthood. Ontogenic Appearance/Disappearance: prenatal, ontogenic changes
occur before birth; birth, ontogenic changes occur at or shortly after birth; 1M-1Y,
ontogenic changes occur between ﬁrst month and year postnatally; –, no change
is seen throughout development. Adapted from reference (McCarver and Hines,
2002).
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increase and conservative doses based on bodyweight adjustments
can begin to be used. Beyond that, doses can be adjusted based on
factoring in the expression level of the speciﬁc enzyme involved
with its metabolism. (Bartelink et al., 2006). It must be cautioned
that efﬁcacy monitoring may be more difﬁcult during the early
stages of development, and thus a reasonable exposure level to
achieve a safe and effective response needs to be established. This
can be extrapolated from adult studies, and carries more risk if it
is derived from animal models.
EXCRETION
Drug excretion by the kidney is primarily controlled by glomeru-
lar ﬁltration, tubular secretion, and tubular reabsorption. These
processes are inﬂuenced by nephrogenesis in the infant and the
different routes mature at different rates. In the newborn, both
glomerular ﬁltration and active secretion take about 6 months to
reach full function (Kramer,2009). In that time, the glomerular ﬁl-
tration rate (GFR) goes from about 13 mL/min/1.73 m (Milne and
Bruss, 2008) to 100mL/min/1.73m (Milne andBruss, 2008). Then
afterward, children continue develop to become extremely rapid
clearers with a GFR close to 130 mL/min/1.73 m (Milne and Bruss,
2008) by age 3. (Kearns et al., 2003). Passive reabsorption of drugs
along the proximal tubular walls does not seem to be affected by
age. These variables result in the need for individualization of age
appropriate doses in drugs that have extensive renal elimination.
Therefore, ﬂexible dosing formulations and/or therapeutic drug
monitoring are required to maintain safe and efﬁcacious expo-
sure levels. For example, gentamicin is eliminated primarily by
glomerular ﬁltration necessitating a decrease in dosing intervals
in infants. Inadequate knowledge of ontogenic changes in GFR
may result in potential toxic or subtherapeutic exposureof this
drug if the ontogeny of renal function is not accounted for when
dosing (Brion et al., 1991).
Dosing must be determined based on the main route of excre-
tion: glomerular ﬁltration or active secretion and if tubular
reabsorption plays a signiﬁcant role. In the ﬁrst 7 days, serum
creatinine may not provide accurate GFR estimates so dosage
adjustments can be made based on gestational age (Bartelink et al.,
2006; Kramer, 2009). After the ﬁrst week of life, creatinine levels
become a better predictor of GFR through the Schwartz formula
(K × L/Scr), which factors in the length (L), serum creatinine
(Scr) and a ratio constant (K) that changes based on the child’s age
(Bartelink et al., 2006). Using this estimate, one can adjust the dose
of drug similarly to the adjustment in renal impairment. If active
secretion is signiﬁcant it can be estimated by comparing total renal
clearance values to GFR values and adjustments can be made by
the ratio comparison of this value (Kramer, 2009).
POPULATION PHARMACOKINETICS USING NON-LINEAR
MIXED EFFECT MODELS
There are several PBPK modeling programs that are available for
use and offer ﬂexibility for pediatric modeling (Björkman, 2005;
Bartelink et al., 2006; Läer et al., 2009; Johnson and Rostami-
Hodjegan, 2011; Allegaert et al., 2012). One example of the
development of PBPK model integrating development changes
in ADME that are transformed into one model was proposed by
Bartelink et al. (2006). The effects on VD, the theoretical volume
needed to provide the concentration found in blood plasma for a
given dose, largely determine the ﬁrst dose and effects on clearance
determine the maintenance dose. After the dose is adjusted for the
effects of VD and clearance initially, further dose modiﬁcations
need to bemade periodically based on changes in theVD, clearance
and potentially absorption effects. This gives a rational method for
dosing and can be built upon with further, top down PBPK meth-
ods. PBPK models can also be reﬁned to account for changes in
the data that result from development including a developmen-
tal shift in the kinetics that alter the rates of elimination, changes
in levels of drug metabolites that may cause adverse responses,
changes in body composition/weight, and changes in PK that arise
from different diseases, e.g., hepatic impairment (Bartelink et al.,
2006; Läer et al., 2009; Johnson and Rostami-Hodjegan, 2011;
Allegaert et al., 2012). Other factors like changes in GI motility,
water intake and output, and food effects can also alter model-
ing. However, these models does not account for differences in
pharmacodynamics, mostly due to fact that very little informa-
tion exists (Kearns et al., 2003). Ultimately, the PBPK application
requires continuous reﬁnement by integrating the results of ongo-
ing research elucidating changes that occur in the neonatal to
infant stages of development and in vitro information to increase
our understanding of dosing schemes (Kearns et al., 2003).
Since Population Based PK approaches are top down meth-
ods, they require existing data from a population and utilize
data evaluation and iterations on speciﬁc covariates to make a
dosing decision. To achieve this goal De Cock et al. (2011; Björk-
man, 2005) have provided a method that uses non-linear mixed
effect statistical tools to enable individualized dosing regimens
for children of different body weights, ages, and genetic back-
grounds. This model is preferred in pediatrics not only because
it gives accurate predictions based on a wide variety of covari-
ates, but it also allows for the analysis of sparse datasets that are
available as a result of the lack of samples that can be taken in
pediatric research. Building these models requires three steps that
are listed below (Björkman, 2005; Läer et al., 2009; Johnson and
Rostami-Hodjegan, 2011; Allegaert et al., 2012):
(1) Structural model – This decides the speciﬁc trend patterns
to analyze, how many compartments relevant to the pharma-
cokinetic study will be used (e.g., central, peripheral, CNS,
etc.) and the ﬁxed effects that the model will explore, such as
clearance and/or VD.
(2) Statistical sub-model – This looks at inter-individual variabil-
ity between all subjects, and intra-individual variability within
individual subjects, along with residual variability.
(3) Covariate sub-model – This step expresses relationships
between covariates of which can be individual differences
like age, body weight, genetic proﬁle or time-varying differ-
ences like renal function, hemodynamic parameters, and body
temperature.
From these three models a covariate analysis can be performed
to determine what patient speciﬁc factors cause a signiﬁcant dif-
ference above the normal variability. Consequently, the optimal
dose for a patient can be determined based on the individual char-
acteristics of the patient (Björkman, 2005). It’s important to note
that the three models mentioned above are inter-related and the
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process of ﬁnding a model that can adequately describe data is
where the challenge lies in these studies. Nonetheless, if this is
done properly it can lead to information that demonstrates the
impact of developmental changes on pharmacokinetic values.
This model was recently put into action in 2009 by Pﬁzer’s
Global Research and Development team for their patented prod-
uct Sildenaﬁl, which can be used in children to treat chronic
pulmonary hypertension of the newborn and is diagnosed in 1.9
out of 1000 live births (Mukherjee et al., 2009). Sildenaﬁl goes
through extensive hepatic metabolism (N-demethylation to UK-
103320), primarily by CYP3A4 (79%) and CYP2C9 (20%) and
renal clearance is minimal. CYP3A7 may be involved but its role is
unclear, therefore rapid development of CYP enzymes may poten-
tially affect sildaneﬁl’s PK during the neonatal period. Clinical
trials were done with 36 full-term neonates diagnosed with this
condition that were administered intravenous infusions of silde-
naﬁl within 72 h at different doses and dose rates (Mukherjee et al.,
2009). A mixed effects pharmacokinetic model that included two-
compartment disposition of sildenaﬁl and its metabolite’s clear-
ance was used to describe plasma concentration-time data. This
model looked at covariates such as postnatal age, weight at screen-
ing, and gender compared to the ﬁxed effects of clearance and VD.
An increase in sildenaﬁl clearance with postnatal age was the only
signiﬁcant covariate effect (Mukherjee et al., 2009). The clearance
in the 1-day old subject was 0.84L/h, which based on allometric
scaling, is equivalent to 8.05l/h/70 kg or one third of the adult silde-
naﬁl clearance (24l/h/ kg). After days 7 the clearance increased to
2.58 L/h, which accurately scales to adult values (Mukherjee et al.,
2009). The data was then analyzed by a Top Down population
based PK model that incorporated known physiological factors
inﬂuencing sildenaﬁl using non-linear mixed effects to determine
how this parameter is affected based on the covariate of age.
CURRENT PROGRESS, SHORTCOMINGS, AND FUTURE
POTENTIAL
In the last decade, providing childrenbetter access to safe and effec-
tive medications has become a major agenda of many countries.
This has come about due to revolutionary initiatives by WHO,
the EU, the WHA, and the FDA that have led to the formation
of the international alliance for better medicines for children in
2006 (Gazarian, 2009). The objectives of this alliance are to stim-
ulate research into children’s medicines and to enact systematic
strategies to promote quality use of medications (Shirkey, 1968).
In the United States, the legislation to address pediatric needs
ﬁrst came about in 1997 with the FDA modernization act. This
ended up becoming a trial and error for the resurgence in pediatric
clinical pharmacology and drug development that has occurred
from the BPCA and the Pediatric Research Equity Act (PREA)
in the past decade (Hoppu et al., 2012). The effectiveness of this
legislation has come from providing a mix of requirements and
incentives to the pharmaceutical industry. While PREA is required
by law, BPCA is voluntary. Under PREA, the FDAand the company
determine if a new drug will have indicated use in the pediatric
population. If it doesn’t, the requirement is waived and the process
ends (Hoppu et al., 2012). If it does have an indication, clini-
cal trials are performed and an agreement is made on the labeling
requirements for this product to account for pediatric use. If a drug
has PREA tests performed, the company may also have the option
to include BPCA tests as well (United States GovernmentAccount-
ability Ofﬁce, 2011). This voluntary procedure can be done for
the new drug or drugs already on the market and is incentivized
through a 6 month patent extension on the drug. Through this
process, a variety of unlabeled uses can be researched.
A recent analysis of nine antihypertensive medications demon-
strated that there was a ratio of net economic return to cost of 17
when these drugs were tested under these provisions (Baker-Smith
et al., 2008; Hoppu et al., 2012; Salunke and Breitkreutz, 2013;
European Pediatric Formulation Initiative, 2014). Subsequently,
this has been very popular and has resulted in“365 trials being per-
formed for 153 medicines between December 1997–2007, which
has resulted in 137 labeling changes, 26% of which included the
addition of safety information to improve pediatricmedicines use”
(Hoppu et al., 2012). Despite these successes, the incentives in this
legislation are mainly focused on drugs that have patent potential.
Many of these drugs have very little use in the pediatric popula-
tions, thus many drugs commonly used in children have yet to be
sufﬁciently studied (Hoppu et al., 2012). To stimulate research in
this area, the US National Institute of Health, through the Insti-
tute of Child Health and Human Development, has reﬁned an
approach to facilitate pediatric clinical drug trials through the
Pediatric Trial Network that will focus primarily on the study of
off-patent medicines prioritized as part of the provisions of BPCA
(Hoppu et al., 2012).
Outside of the United States, the impact of this legislation has
been minimally successful. Perhaps the greatest triumph has been
the establishment of a listing of the most efﬁcacious, safe, and
cost-effective medicines for priority conditions, known as the List
of Essential Medicines for Children (Hoppu et al., 2012). Beyond
that, there has been minimal progress and many countries will
not even be able to beneﬁt from the research being performed by
organizations from the United States due to the reluctance in shar-
ing data collected on pediatric medicines. To make matters worse,
many times the actual research done by US organizations is on for-
eign soil. So, it appears that volunteers are participating in research
that won’t beneﬁt children from their own country. Therefore,
despite the successes in producing legislation and results in the
USA, these studies indicate many improvements are needed to
make this truly a global effort to develop better medicines for
children.
While a great deal of research has been done investigating
anatomical and metabolism ontogeny and its role in drug ADME,
there still remains a large amount of unknowns. Much work has
been done in identifying these unknowns by working groups of
the Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD). Some of the most impor-
tant knowledge gaps were listed as full understanding of ontogeny
of additional drug metabolizing enzymes, transporters, and phys-
iological changes of the GI tract, liver, and kidney (Abdel-Rahman
et al., 2012). This illustrates that while much research has been
done in this area, our knowledge regarding ontogenic changes
is still incomplete. The working group also lists developmental
changes in organ perfusion as well as limited literature on aged-
based PK of many pharmaceuticals needed to build more accurate
PBPK databases.
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Clearly, an ontogenic appreciation of organ speciﬁc trans-
porter expression and function must be obtained in order to fully
understand ADME and Pharmacodynamics across all pediatric
age based populations. It would be important to focus efforts on
the transporters identiﬁed by the International Transporter Con-
sortium (ITC) for their relevance to ADMET ﬁrst, as a series of
decision trees to evaluate function and their role in drug–drug
interactions is at the forefront of pharmaceutical research (Inter-
national Transporter Consortium et al., 2010; Zamek-Gliszczynski
et al., 2012, 2013; Giacomini et al., 2013; Tweedie et al., 2013).
Several transporter isoforms were selected by the ITC to be of clin-
ical importance for drug development including P-glycoprotein
(ABCB1), bile salt export protein (ABCB11),multidrug resistance-
like protein 2 (ABCC2), breast cancer resistance protein (ABCG2),
organic anion transporting polypeptides (SLCO1A2, 1B1, 1B2,
and 2B1), organic anion transporters (SLC22A6-8, 11), organic
cation transporters (SLC22A1-3), multidrug and toxin extrusion
proteins (SLC47A1 and 2; International Transporter Consortium
et al., 2010; Zamek-Gliszczynski et al., 2012). It is anticipated
that these isoforms would also be of greater priority in pediatric
patients.
Of particular relevance to the pharmacogenomic area has been
the limited number of case studies where the impacts of genetic
polymorphisms in drug metabolizing enzymes and transporters
across pediatric patients have been studied. While understanding
basal expression levels and function is prerequisite, personalized
dosing for pediatric subpopulations is very important to consider
for improving therapeutic outcomes. The ITCdid investigate some
common genetic polymorphisms and concluded that a signiﬁcant
level of evidence supported further investigation into OATP1B1
(c.521T > C, p.V174A, rs4149056) and BCRP (c.421C > A,
p.Q141K, rs2231142; Giacomini et al., 2013). Interestingly, a clin-
ical oncology groups study of pediatric patients revealed that
OATP1B1 isoforms were present in 1279 out of 1883 cancer
patients receiving high dose methotrexate therapy (Ramsey et al.,
2013). Lower clearance rates were observed with several polymor-
phic patients and appeared to be associated with higher toxicity.
These outcomes appeared to be most severe with the SLCO1B1
SNP rs4149056 (37041T > C). Dose lowering adjustments and
higher hydration rates should be required in children carrying
these polymorphic phenotypes. Other studies in children possess-
ing SLCO1B1 polymorphisms were not revealed in our literature
search, although their effects on HIV protease inhibitors which
are used globally in pediatric patients should be of some concern
(Giacomini et al., 2013).
Another NICHD working group has also be established to dis-
cuss formulation based changes that must be made for compliant
use bypediatric patients (Giacoia et al., 2008,2012).While this area
appears to be outside the scope of this review, it is important to
note that formulation changesmay very well effect PK andmust be
taken into account during pediatric drug development. For exam-
ple, certain excipients can interact with transporters and inﬂuence
absorption (Constantinides and Wasan, 2007; Werle, 2008; Goole
et al., 2010). The European and United States (US) Paediatric For-
mulation Initiatives (PFIs) have collaborated on establishing the
STEP (safety and toxicity of excipients for pediatrics) database
to detail risks associated with excipients utilized in formulations
for infants, toddlers and children (Salunke et al., 2012, 2013). The
effects of these excipients on controlling drug performance needs
to be fully assessed with respect to safety and toxicity, which may
occur through transporter interactions.
CONCLUSION
Rational drug dose adjustments to provide children, particularly
in the neonatal to toddler age ranges, safe and efﬁcacious expo-
sure must be decided through a comprehensive knowledge of how
changes in physiology affect PK during development. Currently
our knowledge of many of these factors is limited and a greater
effort needs to be made to determine ontogenic factors that inﬂu-
ence ADME. Furthermore, development of an understanding of
these factors throughout pediatric populations in the world is
needed to meet the global challenges facing us. Upon accumu-
lation of this data, the results can be used to reﬁne pediatric PBPK
and population based PK models. As these models are further
built on more data, dose adjustments may allow targeted clinical
research that can be enhanced with the use of non-linear mixed
effects models to predict pediatric dosing in speciﬁc age-based
populations. If pediatric medicines are to reach a level where these
populations are no longer considered therapeutic orphans, then
the search to ﬁnd the best treatment options for children must
continue through targeted scientiﬁc research and the support of
legislation to provide incentives to this research. We as a ﬁeld
must take up an advocacy role so that the words of Dr. Shirkey
are no longer accurate 50 years from now in 2062, on the 100th
anniversary of his infamous assertion.
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